Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
- S-1/A IPO registration
- 1.1 EX-1.1
- 3.1 EX-3.1
- 3.2 EX-3.2
- 3.3 EX-3.3
- 3.4 EX-3.4
- 4.2 EX-4.2
- 4.3 EX-4.3
- 5.1 EX-5.1
- 10.1 EX-10.1(A)
- 10.1 EX-10.1(B)
- 10.2 EX-10.2
- 10.3 EX-10.3
- 10.4 EX-10.4
- 10.5 EX-10.5(A)
- 10.5 EX-10.5(B)
- 10.5 EX-10.5(C)
- 10.6 EX-10.6(A)
- 10.6 EX-10.6(B)
- 10.6 EX-10.6(C)
- 10.7 EX-10.7
- 10.8 EX-10.8
- 10.9 EX-10.9
- 10.10 EX-10.10
- 10.11 EX-10.11
- 10.12 EX-10.12(A)
- 10.12 EX-10.12(B)
- 10.13 EX-10.13
- 10.14 EX-10.14
- 23.1 EX-23.1
- EX-FILING FEES Ex-filing Fees
Associated filings
- 13 Nov 23 424B4 Prospectus supplement with pricing info
- 13 Nov 23 EFFECT Notice of effectiveness
-
6 Nov 23 S-1/A IPO registration (amended)
- 1 Nov 23 S-1/A IPO registration (amended)
- 20 Oct 23 S-1 IPO registration
CRGX similar filings
Filing view
External links
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the use in this Registration Statement No. 333-275113 on Form S-1 of our report dated September 1, 2023, (November 6, 2023, as to the effects of the reverse stock split described in Note 15) relating to the financial statements of Cargo Therapeutics, Inc. We also consent to the reference to us under the heading “Experts” in such Registration Statement.
/s/ Deloitte & Touche LLP
San Francisco, California
November 6, 2023